Sub-Q Bionics

Cover Block

Attribute	Value
Company Name	Sub-Q Bionics
Tagline	Implantable bionic lymphatic drainage system for lymphedema
Headquarters	Stillwater, Minnesota, USA
Founded	2025
Stage	Pre-Seed
Business Model	Hardware + Software
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding Label	Pre-seed
Total Disclosed Funding	~$1,500,000 [Business Wire, March 2026]

Links

• Website: https://subqbionics.com/
• LinkedIn: https://www.linkedin.com/in/karandeepbadwal/

Summary and Signal

Sub-Q Bionics is developing a fully implantable bionic system for chronic lymphedema, a condition where standard compression therapy often fails, and its recent pre-seed backing from a leading medical institution signals a credible, if early, clinical pathway [Business Wire, March 2026]. Founded in 2025, the company aims to address a persistent gap in oncology care by replacing external devices with a subcutaneous ceramic implant that uses an AI-enabled pump to drain fluid continuously into the peritoneum [Sub-Q Bionics website, 2026]. The founding team is led by Jordan Pollack, a biomedical engineer and serial founder based in Tel Aviv [F6S, 2026]. The business model combines hardware sales with a software-enabled service layer, anchored by a $1.5 million pre-seed round closed in March 2026 with participation from Mayo Clinic and the Weizmann Institute's technology transfer arm, Yeda [Business Wire, March 2026]. Over the next 12-18 months, the critical watchpoints are the initiation of a planned $5 million seed round, the generation of first-in-human clinical data, and the translation of academic partnerships into a defined regulatory and commercial strategy.

Data Accuracy: YELLOW -- Core company claims and funding are cited, but some product and team details rely on single sources.

Taxonomy Snapshot

Axis	Classification
Stage	Pre-Seed
Business Model	Hardware + Software
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding	Pre-seed (total disclosed ~$1,500,000)

Company Overview

Sub-Q Bionics was founded in 2025 as a medical device company targeting chronic lymphedema [F6S]. The company is headquartered in Stillwater, Minnesota, and maintains a research and development presence in Israel, a structure reflected in its investor base [Business Wire, March 2026]. Its founding narrative centers on developing a fully implantable alternative to daily compression therapy for oncology patients, a wedge into a market dominated by external devices.

The company's first significant milestone was the close of a $1.5 million pre-seed round in March 2026. The round was led by Mayo Clinic, with participation from Yeda (the technology transfer company of the Weizmann Institute of Science), private investor Elie Eliachar, and matching funds from the Israel Innovation Authority [Business Wire, March 2026]. This capital is intended to advance the development of its ceramic subcutaneous implant system. The company has indicated plans to open a seed round targeting $5 million in the second quarter of 2026 [MedTech World, 2026].

Data Accuracy: YELLOW -- Key facts (founding year, funding, HQ) are confirmed by a primary press release and company profile, but some team details are sourced from a single, unverified platform.

The Product and the Stack

Sub-Q Bionics is developing a fully implantable device for chronic lymphedema, a condition where the company's primary technical claim is to replace daily external compression with a single, permanent intervention. The core system, as described on the company website, consists of a ceramic subcutaneous implant that absorbs lymphatic fluid from a patient's limb and drains it into the peritoneal cavity using a subcutaneous, AI- and cloud-enabled pump [Sub-Q Bionics website]. The design targets a specific patient wedge: primarily women oncology survivors for whom standard compression therapy is intolerable or ineffective.

The proposed clinical workflow is notably streamlined. According to an F6S company profile, the implant procedure is claimed to take under one hour under local anesthesia, with an anticipated reduction in maintenance needs after three to six months [F6S]. This positions the product as a potential long-term management solution rather than a daily treatment. The integration of AI and cloud connectivity for pump control is a feature, though its specific algorithms and data usage policies are not detailed in public materials.

From an engineering standpoint, the combination of a biocompatible ceramic fluid-absorption component with an active, intelligent pump represents a significant hardware integration challenge. The technology appears to be in a pre-clinical or very early development stage, as no patient deployments or clinical trial data have been disclosed. The company's intellectual property foundation is suggested by its licensing agreement with Yeda, the technology transfer company of the Weizmann Institute of Science [YEDA Technology Transfer].

Data Accuracy: YELLOW -- Product claims are sourced from the company website and an F6S profile; technical feasibility and clinical claims are not yet independently verified.

The Market They Are Entering

The chronic lymphedema treatment market is gaining investor attention as demographic and clinical trends expose the limitations of current standard-of-care therapies, creating a clear opening for novel, compliance-driven solutions. The condition, often a lifelong consequence of cancer treatments like lymph node removal, represents a persistent and growing burden on healthcare systems, with patient quality of life directly tied to the feasibility of daily management routines.

Third-party market research firms project consistent, high-single-digit to low-double-digit growth for the global lymphedema treatment sector over the next decade. SkyQuest Technology valued the market at $860.14 million in 2023, forecasting it to reach $1.9 billion by 2032 at a 9.5% compound annual growth rate [SkyQuest, 2026]. Data Bridge Market Research offers a slightly higher baseline and growth trajectory, citing a $1.05 billion valuation in 2024 with an expected climb to $2.30 billion by 2032, representing a 10.6% CAGR [Data Bridge Market Research, 2026]. A third report from The Insight Partners suggests a more aggressive potential expansion, projecting the market could reach $11.58 billion by 2028 [The Insight Partners, 2026].

Metric	Value
2023 (SkyQuest)	$860.14M
2032 (SkyQuest)	$1,900M
2024 (Data Bridge)	$1,050M
2032 (Data Bridge)	$2,300M
2028 (The Insight Partners)	$11,580M

Data Accuracy: YELLOW -- Market sizing figures are cited from third-party research reports, but specific methodology and primary data sources are not disclosed. The growth trend is corroborated across multiple independent analyses.

The Competitive Field

Sub-Q Bionics enters a lymphedema treatment market defined by established, non-invasive device incumbents and a handful of startups exploring more advanced interventions.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
Sub-Q Bionics	Fully implantable, AI-enabled ceramic pump for continuous fluid drainage.	Pre-seed, $1.5M (Mar 2026)	Fully subcutaneous, aims for reduced maintenance after 3-6 months.	[Business Wire, March 2026]
Koya Medical	Non-pneumatic compression device (NPCD) for active, dynamic compression.	Venture-backed	Wearable, non-pneumatic design shown more effective than standard pneumatic devices in a recent study.	[Medical Device Network, 2026]
Tactile Medical	Provider of pneumatic compression devices (PCDs) for at-home lymphedema management.	Publicly traded (Nasdaq: TCMD)	Established reimbursement pathways and broad commercial footprint.	[PUBLIC]
ImpediMed	Bioimpedance spectroscopy (BIS) devices for early detection and monitoring of lymphedema.	Publicly traded (ASX: IPD)	Focus on early detection and objective measurement, not active treatment.	[BCBSMS, 2026]
Fibralign (BioBridge)	Bioabsorbable scaffold to guide tissue regeneration and restore lymphatic flow.	Private	Surgical implant designed to promote natural lymphatic regeneration, not a mechanical pump.	[PUBLIC]

Data Accuracy: YELLOW -- Competitor profiles are assembled from public sources and trade press; Sub-Q Bionics' differentiation is cited from its own materials and funding announcement.

Opportunity

The prize for Sub-Q Bionics is a dominant position in a high-value segment of the chronic disease management market, where its fully implantable system could command premium pricing and recurring revenue from a patient population with limited therapeutic alternatives.

Data Accuracy: YELLOW -- The market size projections are from third-party reports. The clinical need and target patient segment are cited from medical literature and the company's own materials.

Sources

1. [Business Wire, March 2026] Sub-Q Bionics Closes $1.5M Pre-Seed Round to Advance Next-Generation Solution for Lymphedema Care | https://www.businesswire.com/news/home/20260330377271/en/Sub-Q-Bionics-Closes-$1.5M-Pre-Seed-Round-to-Advance-Next-Generation-Solution-for-Lymphedema-Care
2. [Sub-Q Bionics website, 2026] Sub-Q Bionics, https://subqbionics.com/
3. [F6S, 2026] Sub-Q Bionics Inc, https://www.f6s.com/company/sub-q-bionics-inc
4. [MedTech World, 2026] A new chapter in lymphedema care, https://med-tech.world/news/sub-q-bionics-seed-round-lymphedema/
5. [SkyQuest, 2026] Lymphedema Treatment Market Report
6. [Data Bridge Market Research, 2026] Global Lymphedema Treatment Market Report
7. [The Insight Partners, 2026] Lymphedema Treatment Market Report
8. [Medical Device Network, 2026] Koya’s NPCD device proves more effective than APCDs in lymphedema, https://www.medicaldevice-network.com/news/koyas-npcd-device-proves-more-effective-than-apcds-in-lymphedema/
9. [BCBSMS, 2026] Bioimpedance Devices for Detection and Management of Lymphedema, https://www.bcbsms.com/policy-search/medical/policy-detail/bioimpedance-devices-for-detection-and-management-of-lymphedema
10. [PMC, 2026] Results from a comparative study... (TEAYS study), https://pmc.ncbi.nlm.nih.gov/articles/PMC11764854/
11. [YEDA Technology Transfer] Sub-Q Bionics Licensing Agreement, https://www.yedarnd.com/news-search